PURPOSE: Previous studies showed that anabolic androgenic steroids (AAS) increase vascular resistance and blood pressure (BP) in humans. In this study, we tested the hypotheses 1) that AAS users would have increased muscle sympathetic nerve activity (MSNA) and reduced forearm blood flow (FBF) compared with AAS nonusers and 2) that there would be an association between MSNA and 24-h BP. METHODS: Twelve AAS users aged 31 +/- 2 yr (means +/- SE) and nine age-matched AAS nonusers aged 29 +/- 2 yr participated in the study. All individuals were involved in strength training for at least 2 yr. AAS was determined by urine test (chromatography-mass spectrometry). MSNA was directly measured by microneurography technique. FBF was measured by venous occlusion plethysmography. BP monitoring consisted of measures of BP for 24 h. RESULTS: MSNA was significantly higher in AAS users than that in AAS nonusers (29 +/- 3 vs 20 +/- 1 bursts per minute, P = 0.01). FBF (1.92 +/- 0.17 vs 2.77 +/- 0.24 mL x min(-1) x 100 mL(-1), P = 0.01) and forearm vascular conductance (2.01 +/- 0.17 vs 2.86 +/- 0.31 U, P = 0.02) were significantly lower in AAS users than that in AAS nonusers. Systolic (131 +/- 4 vs 120 +/- 3 mm Hg, P = 0.001), diastolic (74 +/- 4 vs 68 +/- 3 mm Hg, P = 0.02), and mean BP (93 +/- 4 vs 86 +/- 3 mm Hg, P = 0.005) and heart rate (74 +/- 3 vs 68 +/- 3 bpm, P = 0.02) were significantly higher in AAS users when compared with AAS nonusers. Further analysis showed that there was a significant correlation between MSNA and 24-h mean BP (r = 0.75, P = 0.002). CONCLUSIONS: AAS increases MSNA and reduces muscle blood flow in young individuals. In addition, the increase in BP levels in AAS users is associated with augmented sympathetic outflow. These findings suggest that AAS increases the susceptibility for cardiovascular disease in humans.
PURPOSE: Previous studies showed that anabolic androgenic steroids (AAS) increase vascular resistance and blood pressure (BP) in humans. In this study, we tested the hypotheses 1) that AAS users would have increased muscle sympathetic nerve activity (MSNA) and reduced forearm blood flow (FBF) compared with AAS nonusers and 2) that there would be an association between MSNA and 24-h BP. METHODS: Twelve AAS users aged 31 +/- 2 yr (means +/- SE) and nine age-matched AAS nonusers aged 29 +/- 2 yr participated in the study. All individuals were involved in strength training for at least 2 yr. AAS was determined by urine test (chromatography-mass spectrometry). MSNA was directly measured by microneurography technique. FBF was measured by venous occlusion plethysmography. BP monitoring consisted of measures of BP for 24 h. RESULTS: MSNA was significantly higher in AAS users than that in AAS nonusers (29 +/- 3 vs 20 +/- 1 bursts per minute, P = 0.01). FBF (1.92 +/- 0.17 vs 2.77 +/- 0.24 mL x min(-1) x 100 mL(-1), P = 0.01) and forearm vascular conductance (2.01 +/- 0.17 vs 2.86 +/- 0.31 U, P = 0.02) were significantly lower in AAS users than that in AAS nonusers. Systolic (131 +/- 4 vs 120 +/- 3 mm Hg, P = 0.001), diastolic (74 +/- 4 vs 68 +/- 3 mm Hg, P = 0.02), and mean BP (93 +/- 4 vs 86 +/- 3 mm Hg, P = 0.005) and heart rate (74 +/- 3 vs 68 +/- 3 bpm, P = 0.02) were significantly higher in AAS users when compared with AAS nonusers. Further analysis showed that there was a significant correlation between MSNA and 24-h mean BP (r = 0.75, P = 0.002). CONCLUSIONS: AAS increases MSNA and reduces muscle blood flow in young individuals. In addition, the increase in BP levels in AAS users is associated with augmented sympathetic outflow. These findings suggest that AAS increases the susceptibility for cardiovascular disease in humans.
Authors: Octávio Barbosa Neto; Gustavo Ribeiro da Mota; Carla Cristina De Sordi; Elisabete Aparecida M R Resende; Luiz Antônio P R Resende; Marco Antônio Vieira da Silva; Moacir Marocolo; Rafael Silva Côrtes; Lucas Felipe de Oliveira; Valdo José Dias da Silva Journal: Clin Auton Res Date: 2017-10-10 Impact factor: 4.435
Authors: Richard D Rothman; Rory B Weiner; Harrison Pope; Gen Kanayama; Adolph M Hutter; Michael A Fifer; G William Dec; Aaron L Baggish Journal: BMJ Case Rep Date: 2011-08-17
Authors: H S Melsom; C M Heiestad; E Eftestøl; M K Torp; K Gundersen; A K Bjørnebekk; P M Thorsby; K O Stensløkken; J Hisdal Journal: Sci Rep Date: 2022-06-11 Impact factor: 4.996
Authors: Ana Luiza C Sayegh; Marcelo R Dos Santos; Adriana O Sarmento; Francis R de Souza; Vera M C Salemi; Viviane T Hotta; Akothirene Cristhina D B Marques; Heidrum H Krämer; Ivani C Trombetta; Charles Mady; Maria Janieire de Nazaré Nunes Alves Journal: ESC Heart Fail Date: 2017-03-30
Authors: Marcelo R Dos Santos; Ana L C Sayegh; Rafael Armani; Valéria Costa-Hong; Francis R de Souza; Edgar Toschi-Dias; Luiz A Bortolotto; Mauricio Yonamine; Carlos E Negrão; Maria-Janieire N N Alves Journal: Clinics (Sao Paulo) Date: 2018-05-21 Impact factor: 2.365
Authors: Giuseppe Davide Albano; Francesco Amico; Giuseppe Cocimano; Aldo Liberto; Francesca Maglietta; Massimiliano Esposito; Giuseppe Li Rosi; Nunzio Di Nunno; Monica Salerno; Angelo Montana Journal: Healthcare (Basel) Date: 2021-01-19
Authors: Dain W Jacob; Jennifer L Harper; Clayton L Ivie; Elizabeth P Ott; Jacqueline K Limberg Journal: Exp Physiol Date: 2021-07-10 Impact factor: 2.858